Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03066622 · ClinicalTrials.gov registry record · Phase 4

Olanzapine for Acute Headaches

A Phase 4 study of Headache, sponsored by HealthPartners Institute.

Completed
Registry status
Phase 4
Development phase
122
Enrollment target
1
Study location

NCT03066622 is a Phase 4 study of Headache that has completed, run by HealthPartners Institute. The registered enrollment target is 122 participants, below the 152-participant average among 35 other Headache trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03066622, a Phase 4 study of Headache, has completed, sponsored by HealthPartners Institute.

COMPLETED
Registry status
Phase 4
Development phase
122 participants
Enrollment target
1
Study location

Study Summary

This trial is a prospective, randomized, feasibility trial with the primary aim of comparing how well oral rapidly dissolving olanzapine controls primary headache pain when compared to the current treatment strategies used in emergency departments which often require intravenous or intramuscular medications.

Conditions Studied

Interventions

  • DRUG Standard of Care as per attending physician
  • DRUG 5mg rapidly dissolving olanzapine

Study Locations (1)

Minnesota

  • Regions Hospital - Saint Paul

Trial Details

FieldValue
Enrollment Target 122 participants
Start Date 2016-07
Est. Completion 2018-05-20
Phase Phase 4

Sponsor

HealthPartners Institute

146 total trials

What the Registry Record Tells You About NCT03066622

The ClinicalTrials.gov registry entry for NCT03066622 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 152-participant average among 35 other Headache trials with a reported enrollment target (20% lower). The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Headache appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care as per attending physician is the first listed.

NCT03066622 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT03066622 about?

NCT03066622 is a clinical study titled "Olanzapine for Acute Headaches". This trial is a prospective, randomized, feasibility trial with the primary aim of comparing how well oral rapidly dissolving olanzapine controls primary headache pain when compared to the current treatment strategies used in emergency departments which often require intravenous or intramuscular med...

What is the current status of trial NCT03066622?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 122 participants. The study started on 2016-07. Estimated completion is 2018-05-20.

What conditions does trial NCT03066622 study?

This clinical trial studies the following conditions: Headache.

What interventions are being tested in trial NCT03066622?

The interventions under investigation include: Standard of Care as per attending physician (DRUG), 5mg rapidly dissolving olanzapine (DRUG).

Who is sponsoring clinical trial NCT03066622?

This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03066622 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Headache

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.